News

Neurology News Network for the week of September 15, 2018.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the importance of interaction between general neurology and epileptologists.

The monoclonal antibody is now the second member of the CGRP inhibitor class to be approved by the FDA.

The third-generation, small molecule CGRP antagonist is the second Biohaven migraine therapy to reach human clinical development.

Jason Lerner MD, discussed the recently opened Adolescent Epilepsy Center at UCLA, a clinic that offers comprehensive care for teens with epilepsy.

TSC has shown potential to become the first approved therapy for acute stroke, able to be administered in the ambulance.

After its approval in May for pediatric MS, the data displayed its efficacy in comparison to standard therapy.

The director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about the potential of a DHE therapy for acute migraine treatment.

Creativity, a human ability that provides artistic, organizational, and scientific innovation, moves the world forward. Do drugs that alter perception help or hinder that process?

By the open-label extension’s end, those treated with pitolisant showed a decrease in ESS score by 6.2 from baseline.

The co-director of the UPMC’s Center for Endovascular Therapy spoke about the gains that stroke care has made in the last few years.

The idea of marijuana as a panacea for neurologic conditions has come into play, leading to a need for clarification about the use of CBD for these conditions.

Rachel Salas, MD, a Johns Hopkins Associate Professor, spoke about insomnia, a very individualized disorder, and the need for moving toward precision medicine.

Study findings revealed that AED clearance significantly changes by the first trimester for levetiracetam and by the second trimester for oxcarbazepine and topiramate.

As a phase III trial of DHE gets underway, the director of the Dartmouth Headache Clinic at Dartmouth-Hitchcock Medical Center spoke about its clinical history in the United States.

The director of the Comprehensive Multiple Sclerosis Center at Stony Brook Neuroscience Institute spoke about the importance of early treatment and identification of the condition.

A real-world study in relapsing MS helped develop a risk score scale to aid in disability progression prediction, and thus, treatment strategies.

The MS expert discussed the field's recent foray into treating progressive forms of the disease and what is in development.

Xenon Pharmaceuticals announced the expansion of its ion channel pipeline as a result of feedback from the FDA.

The director of the Epilepsy Program at the Banner University Medical Center spoke about the needs in patient populations with epilepsy.

The Johns Hopkins Associate Professor discussed the current of state sleep and also dove into the therapeutic landscape of sleep apnea.

While there isn’t one agent Coyle believes is held above the rest, she noted that the oral therapies have become popular due to ease of administration.

Also known as S48168, it was previously granted Orphan Drug designation as well as a Rare Pediatric Disease designation in 2015 for Duchenne Muscular Dystrophy.

The approval was based on bioavailability studies which compared the tablet formulation of riluzole to the oral suspension formulation.

The director of the electromyography laboratory and a professor of neurology at Cedars-Sinai discussed the misdiagnosis of the rare condition.

Neurologic complications remain a significant cause of long-term disability. Understanding and recognizing these conditions is crucial in effectively managing HIV.

The dual-therapy regimen will be compared to high-dose tPA monotherapy, the standard of care, in patients with distal blood clots post-stroke.

Previously, in a 5-year phase I-II trial, the rAAV vector serotype rh.10 showed promising safety data.